Healthcare / Biotechnology
Exclusive insider sentiment analysis for the Biotechnology sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-17 20:01 | 2026-07-15 | ARQT | Arcutis Biotherapeutics, Inc. | Welgus Howard G. | Director | Biotechnology | OPT+S | $26.91 | 4,730 | $127,284 | 37,109 | -11.3% |
| 2026-07-17 20:15 | 2026-07-15 | CGON | CG Oncology, Inc. | POST LEONARD E | Director | Biotechnology | OPT+S | $71.17 | 1,000 | $71,170 | 0 | -100.0% |
| 2026-07-18 01:43 | 2026-07-17 | MNKD | MANNKIND CORP | Thomson David | Officer; EVP Genl Counsel & Secretary | Biotechnology | OPT+S | $4.05 | 24,109 | $97,641 | 797,554 | -2.9% |
| 2026-07-18 01:44 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Hanson Kristopher | Officer; General Counsel | Biotechnology | SALE | $36.82 | 16,508 | $607,871 | 145,823 | -10.2% |
| 2026-07-18 01:45 | 2026-07-16 | LYEL | Lyell Immunopharma, Inc. | Innovative Cellular Therapeutics Holdings Ltd | 10% owner | Biotechnology | SALE | $13.73 | 10 | $137 | 2,857,490 | 0.0% |
| 2026-07-18 01:45 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Lillie James Woodruff | Officer; Chief Scientific Officer | Biotechnology | SALE | $36.88 | 18,267 | $673,636 | 224,462 | -7.5% |
| 2026-07-18 01:46 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Kroeger Christopher A. | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $36.87 | 147,639 | $5,443,716 | 1,246,455 | -10.6% |
| 2026-07-18 01:42 | 2026-07-17 | MNKD | MANNKIND CORP | Binder Steven B. | Director | Biotechnology | OPT+S | $4.06 | 52,485 | $213,089 | 824,918 | -6.0% |
| 2026-07-18 01:43 | 2026-07-15 | MPLT | MapLight Therapeutics, Inc. | Foff Erin Pennock | Officer; Chief Medical Officer | Biotechnology | SALE | $36.78 | 47,158 | $1,734,490 | 298,901 | -13.6% |
| 2026-07-17 23:23 | 2026-07-15 | ADPT | Adaptive Biotechnologies Corp | LO FRANCIS | Officer; Chief People Officer | Biotechnology | OPT+S | $22.59 | 105,762 | $2,389,164 | 230,713 | -31.4% |
| 2026-07-17 23:00 | 2026-07-15 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Officer; President and COO | Biotechnology | OPT+S | $33.99 | 4,000 | $135,974 | 174,209 | -2.2% |
| 2026-07-17 22:31 | 2026-07-15 | CORT | CORCEPT THERAPEUTICS INC | Mokari Atabak | Officer; Chief Financial Officer | Biotechnology | OPT+S | $87.71 | 40,000 | $3,508,276 | 16,130 | -71.3% |
| 2026-07-17 22:38 | 2026-07-15 | CORT | CORCEPT THERAPEUTICS INC | WILSON JAMES N | Director | Biotechnology | SALE | $88.30 | 10,000 | $882,986 | 1,084,543 | -0.9% |
| 2026-07-17 21:31 | 2026-07-15 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $315.56 | 283,154 | $89,351,595 | 0 | -100.0% |
| 2026-07-17 21:36 | 2026-07-17 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $312.00 | 64,628 | $20,163,904 | 0 | -100.0% |
| 2026-07-17 20:05 | 2026-07-16 | GLUE | Monte Rosa Therapeutics, Inc. | Warmuth Markus | Director, Officer; President & CEO | Biotechnology | SALE | $23.18 | 9,500 | $220,219 | 585,038 | -1.6% |
| 2026-07-17 20:05 | 2026-07-15 | PVLA | PALVELLA THERAPEUTICS, INC. | Goin Kathleen | Officer; Chief Operating Officer | Biotechnology | OPT+S | $149.28 | 4,302 | $642,191 | 0 | -100.0% |
| 2026-07-17 20:09 | 2026-07-15 | ARDX | ARDELYX, INC. | RAAB MICHAEL | Director, Officer; President & CEO | Biotechnology | OPT+S | $5.06 | 41,668 | $210,923 | 1,678,366 | -2.4% |
| 2026-07-17 20:10 | 2026-07-15 | KROS | Keros Therapeutics, Inc. | BIENAIME JEAN JACQUES | Director | Biotechnology | BUY | $10.61 | 1,000 | $10,610 | 18,592 | +5.7% |
| 2026-07-17 00:10 | 2026-07-14 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $2.43 | 63,969 | $155,643 | 2,854,072 | +2.3% |
| 2026-07-16 21:39 | 2026-07-14 | GALT | GALECTIN THERAPEUTICS INC | Jamil Khurram | Officer; Chief Medical Officer | Biotechnology | OPT+S | $5.13 | 16,250 | $83,285 | 0 | -100.0% |
| 2026-07-16 21:42 | 2026-07-14 | CELC | Celcuity Inc. | BAKER BROS. ADVISORS LP | Other | Biotechnology | SALE | $102.50 | 3,100,000 | $317,750,000 | 4,372,852 | -41.5% |
| 2026-07-16 21:20 | 2026-07-14 | PTCT | PTC THERAPEUTICS, INC. | Gravier Pierre | Officer; CHIEF FINANCIAL OFFICER | Biotechnology | SALE | $80.35 | 3,494 | $280,743 | 83,986 | -4.0% |
| 2026-07-16 21:08 | 2026-07-14 | ADIL | ADIAL PHARMACEUTICALS, INC. | Coastlands Capital LP | 10% owner | Biotechnology | BUY | $2.69 | 3,233 | $8,691 | 388,308 | +0.8% |
| 2026-07-16 20:45 | 2026-07-15 | MRNA | Moderna, Inc. | Hoge Stephen | Officer; President | Biotechnology | OPT+S | $67.60 | 53,336 | $3,605,514 | 1,483,848 | -3.5% |
| 2026-07-16 20:01 | 2026-07-14 | CRDF | Cardiff Oncology, Inc. | Mohindru Mani | Director, Officer; Chief Executive Officer | Biotechnology | BUY | $1.46 | 34,364 | $50,000 | 59,067 | +139.1% |
| 2026-07-16 20:03 | 2026-07-14 | CRDF | Cardiff Oncology, Inc. | PACE GARY W | Director | Biotechnology | BUY | $1.46 | 687,285 | $1,000,000 | 2,043,661 | +50.7% |
| 2026-07-16 20:07 | 2026-07-15 | INCY | INCYTE CORP | Stein Steven H | Officer; CMO & Head of Late-Stage Dev. | Biotechnology | SALE | $113.05 | 28,237 | $3,192,193 | 26,083 | -52.0% |
| 2026-07-16 20:10 | 2026-07-15 | GLUE | Monte Rosa Therapeutics, Inc. | Champoux Jennifer | Officer; Chief Operating Officer | Biotechnology | OPT+S | $23.38 | 4,351 | $101,730 | 62,371 | -6.5% |
| 2026-07-16 13:00 | 2026-07-15 | VANI | Vivani Medical, Inc. | Williams Gregg | Director, 10% owner | Biotechnology | BUY | $1.26 | 793,650 | $999,999 | 36,912,736 | +2.2% |
| 2026-07-16 13:00 | 2026-07-15 | ANIX | Anixa Biosciences Inc | Titterton Lewis H jr | Director | Biotechnology | BUY | $3.28 | 2,797 | $9,174 | 974,967 | +0.3% |
| 2026-07-16 00:58 | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer; Chief Medical Officer | Biotechnology | OPT+S | $27.28 | 20,407 | $556,672 | 51,384 | -28.4% |
| 2026-07-16 00:58 | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $27.24 | 10,700 | $291,441 | 603,621 | -1.7% |
| 2026-07-15 23:50 | 2026-07-13 | FULC | Fulcrum Therapeutics, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $3.57 | 249,946 | $891,057 | 6,913,329 | +3.8% |
| 2026-07-15 23:36 | 2026-07-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer; Chief Medical Officer | Biotechnology | OPT+S | $86.28 | 7,000 | $603,938 | 32,718 | -17.6% |
| 2026-07-15 20:40 | 2026-07-14 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biotechnology | BUY | $0.87 | 4,300 | $3,754 | 368,385 | +1.2% |
| 2026-07-15 20:15 | 2026-07-14 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $40.00 | 8,210 | $328,437 | 539,817 | -1.5% |
| 2026-07-15 20:05 | 2026-07-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | Biotechnology | BUY | $73.64 | 1,695 | $124,819 | 493,936 | +0.3% |
| 2026-07-15 17:08 | 2026-07-13 | PHVS | Pharvaris N.V. | Modig Berndt | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $34.97 | 2,292 | $80,154 | 132,917 | -1.7% |
| 2026-07-15 01:25 | 2026-07-10 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $303.18 | 60,218 | $18,256,809 | 0 | -100.0% |
| 2026-07-15 01:26 | 2026-07-14 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $305.95 | 145,861 | $44,626,421 | 0 | -100.0% |
| 2026-07-14 23:59 | 2026-07-13 | LQDA | Liquidia Corp | Boyle Dana | Officer; Chief Accounting Officer | Biotechnology | OPT+S | $71.51 | 9,002 | $643,739 | 169,519 | -5.0% |
| 2026-07-15 00:01 | 2026-07-13 | LQDA | Liquidia Corp | Moomaw Scott | Officer; Chief Commercial Officer | Biotechnology | OPT+S | $71.51 | 9,539 | $682,142 | 182,485 | -5.0% |
| 2026-07-15 00:02 | 2026-07-13 | LQDA | Liquidia Corp | Saggar Rajeev | Officer; Chief Medical Officer | Biotechnology | OPT+S | $71.51 | 9,926 | $709,816 | 171,799 | -5.5% |
| 2026-07-15 00:04 | 2026-07-13 | LQDA | Liquidia Corp | Schundler Russell | Officer; General Counsel | Biotechnology | OPT+S | $71.51 | 14,738 | $1,053,926 | 605,962 | -2.4% |
| 2026-07-15 00:05 | 2026-07-13 | LQDA | Liquidia Corp | Adair Jason | Officer; Chief Business Officer | Biotechnology | OPT+S | $71.51 | 7,863 | $562,289 | 217,126 | -3.5% |
| 2026-07-15 00:07 | 2026-07-13 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $71.51 | 35,249 | $2,520,684 | 1,130,426 | -3.0% |
| 2026-07-15 00:08 | 2026-07-13 | LQDA | Liquidia Corp | Kaseta Michael | Officer; CFO and COO | Biotechnology | OPT+S | $71.51 | 20,430 | $1,460,966 | 345,805 | -5.6% |
| 2026-07-15 00:09 | 2026-07-13 | LQDA | Liquidia Corp | Khindri Sanjeev | Officer; Chief Development Officer | Biotechnology | SALE | $71.51 | 1,185 | $84,740 | 65,947 | -1.8% |
| 2026-07-15 00:11 | 2026-07-13 | LQDA | Liquidia Corp | Krepp Sarah | Officer; Chief Human Resource Officer | Biotechnology | OPT+S | $71.51 | 7,864 | $562,361 | 117,178 | -6.3% |
Strategic Analysis
Analyzing insider transactions within the Biotechnology sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.